Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ChAd3-hliNSmut · 1 trial · 1 indication
To evaluate the safety of administering HCV prime-boost vaccinations, ChAd3-hliNSmut and MVA-hilNSmut intramuscularly in healthy volunteers and DAA treated volunteers that were previously infected with HCV
| Arm | Type | Description |
|---|---|---|
| Group 1 (low dose/healthy volunteers) | EXPERIMENTAL | 5 healthy volunteers receiving 1 dose ChAd3-hliNSmut (5x10\*9 vp) IM at week 0 and 1 dose of MVA-hliNSmut (5 X10\*7 pfu) IM at week 8 |
| Group 2 (higher dose/healthy volunteers) | EXPERIMENTAL | 10 healthy volunteers receiving 1 dose ChAd3-hliNSmut (2.5 x10\*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X 10\*8 pfu) IM at week 8 |
| Group 3 (higher dose/HCV cured volunteers) | EXPERIMENTAL | 10 DAA treated volunteers (previously HCV positive) receiving 1 dose ChAd3-hliNSmut (2.5 x10\*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X10\*8 pfu) IM at week 8 |
| Name | Type | Description |
|---|---|---|
| ChAd3-hliNSmut | BIOLOGICAL | Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV |
| MVA-hliNSmut | BIOLOGICAL | Modified Vaccinia Ankara (MVA) vectored vaccine against HCV |
Inclusion Criteria: * Aged at least 18 years on the day of screening and no greater than 65 years on the day of the first vaccination * Resident in or easy access to the trial site for the duration of the study * Available for follow-up for the planned duration of the study * Able and willing (in t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir |
| Abbott Laboratories | ABT | 2 | - | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Undisclosed |
ChAd3-hliNSmut is an investigational vaccine being developed for Hepatitis C. It is currently in Phase 1 clinical development and has completed one trial in the United Kingdom. The vaccine is designed to target Hepatitis C, a viral infection that affects the liver.
ChAd3-hliNSmut is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The company is conducting clinical research on this investigational Hepatitis C vaccine candidate.
ChAd3-hliNSmut is in Phase 1 clinical development. It is an investigational vaccine for Hepatitis C and is not yet approved by regulatory authorities. One Phase 1 trial has been completed, with no active trials currently ongoing.
ChAd3-hliNSmut has been studied in one clinical trial with the identifier NCT03688061, titled 'Class II Invariant Chain HCV Vaccine Study'. This Phase 1 trial was completed in the United Kingdom and enrolled 25 participants, including healthy volunteers aged 18 years and older.
ChAd3-hliNSmut is classified as a monoclonal antibody modality, though it is being studied as a vaccine for Hepatitis C. The trial for this candidate enrolled healthy volunteers and was controlled, but it was not randomized or double-blind.